Endocrine Abstracts

Incretin mimetics, alongside associated hybrid co-agonist peptides, which activate GLP-1 and other receptors are leading the way to more effective therapeutic options for management of obesity and type 2 diabetes. The adipokine apelin, which activates the APJ receptor, has shown anti-diabetic and obesity related therapeutic utility following pre-clinical testing. The present study investigated several novel hybrid co-agonist peptides, derived from exendin-linker-apelin (ELA) a...

Incretin mimetics and associated hybrid co-agonist peptides remain a driving force in improving metabolic control and managing type 2 diabetes and obesity. Additionally, the adipokine apelin which targets the APJ receptor, has displayed positive anti-diabetic and obesity effects in pre-clinical trials. To harness these beneficial effects, two novel dual-agonist unimolecular peptides were developed based on the amino acid sequence of GLP-1 and apelin and named Exendin-Linker-Ap...